Advertisement

Liver Cancer pp 137-144 | Cite as

Screening with Ultrasonography of Patients at High-Risk for Hepatocellular Carcinoma: Thrombocytopenia as a Valid Surrogate of Cirrhosis

  • Sheng-Nan Lu
  • Jing-Houng Wang
  • Kwong-Ming Kee
  • Po-Lin Tseng
Chapter
  • 1.7k Downloads
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 5)

Sequelae of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, including hepatocellular carcinoma (HCC), liver cirrhosis (LC) and their complications, are health burdens of the world. Improving treatment results for early stage HCC makes the screening meaningful. Two-staged HCC screening identifying high risk subjects in the first stage and screening for HCC by ultrasonography (US) in the second stage is a practical and workable concept. The benefit of US screening on high risk groups has been well documented, but “who should be included in the US screening” depends on cost-benefits and considerations of feasibility.

Keywords

Liver Fibrosis Viral Liver Disease Forns Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Afdhal, N.H., and Nunes, D. 2004. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 99: 1160–1174.PubMedCrossRefGoogle Scholar
  2. Boeker, K.H., Haberkorn, C.I., Michels, D., Flemming, P., Manns, M.P., and Lichtinghagen, R. 2002. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin. Chim. Acta 316: 71–81.PubMedCrossRefGoogle Scholar
  3. Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., and Sherman, M. 2001. Surveillance programme of cirrhotic patients for early detection and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251–259.PubMedCrossRefGoogle Scholar
  4. Borroni, G., Ceriani, R., Cazzaniga, M., Tommasini, M., Roncalli, M., Maltempo, C., Felline, C., and Salerno, F. 2006. Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Aliment Pharmacol. Ther. 24: 797–804.PubMedCrossRefGoogle Scholar
  5. Bruix, J., and Sherman, M. 2005. Management of hepa-tocellular carcinoma. Hepatology 5: 1208–1236.CrossRefGoogle Scholar
  6. Chen, T.H., Chen, C.J., Yen, M.F., Lu, S.N., Sun, C.A., Huang, G.T., Yang, P.M., Lee, H.S., and Duffy, S.W. 2002. Ultrasound screening and risk of factors for death from heptocellular carcinoma in a high risk group in Taiwan. Int. J. Cancer 98: 257–261.PubMedCrossRefGoogle Scholar
  7. Colli, A., Fraquelli, M., Casazza, G., Massironi, S., Colucci, A., Conte, D., and Duca, P. 2006. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systemic review. Am. J. Gastroenterol. 101: 513–523.PubMedCrossRefGoogle Scholar
  8. Daniele, B., Bencivenga, A., Megna, A.S., and Tinessa, V. 2004. α-fetoprotein and ultrasonog-raphy screening for hepatocellular carcinoma. Gastroenterology 127: 108–112.CrossRefGoogle Scholar
  9. Di Bisceglie, A.M. 2004. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127: S104–107.PubMedCrossRefGoogle Scholar
  10. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., and Realdi, G. 1997. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463–472.PubMedCrossRefGoogle Scholar
  11. Forns, X., Ampurdanes, S., Llovet, J.M., Aponte, J., Quintó, L., Martínez-Bauer, E., Bruguera, M., Sánchez-Tapias, J.M., and Rodés, J. 2002. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36: 986–992.PubMedGoogle Scholar
  12. Giannini, E., and Testa, R. 2003. The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. Arch. Intern. Med. 163: 2787–2788.PubMedCrossRefGoogle Scholar
  13. Guechot, J., Laudat, A., Loria, A., Serfaty, L., Poupon, R., and Giboudeau, J. 1996. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin. Chem. 42: 558–563.PubMedGoogle Scholar
  14. Imbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y., Poynard, T. and MULTIVIRC Group. 2001. Biochemical markers of liver fibro-sis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069–1075.PubMedCrossRefGoogle Scholar
  15. Kelleher, T.B., and Afdhal, N. 2005. Noninvasive assessment of liver fibrosis. Clin. Liver Dis. 9: 667–683.PubMedCrossRefGoogle Scholar
  16. Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., and Tanaka, E. 2004. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127: S17–26.PubMedCrossRefGoogle Scholar
  17. Leykum, L.K., El-Serg, H.B., Cornell, J., and Papadopoulos, K.P. 2007. Screening for hepato-cellular carcinoma veterans with hepatitis C on disease stage, treatment received, and survival. Clin. Gastroenterol. Hepatol. 5: 508–512.PubMedCrossRefGoogle Scholar
  18. Lu, S.N., Su, W.W., Yang, S.S., Chang, T.T., Cheng, K.S., Wu, J.C., Lin, H.H., Wu, S.S., Lee, C.M., Changchien, C.S., Chen, C.J., Sheu, J.C., Chen, D.S., and Chen, C.H. 2006a. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocel-lular carcinoma in Taiwan. Int. J. Cancer 119: 1946–1952.CrossRefGoogle Scholar
  19. Lu, S.N., Wang, J.H., Liu, S.L., Hung, C.H., Chen, C.H., Tung, H.D., Chen, T.M., Huang, W.S., Lee, C.M., Chen, C.C., and Changchien, C.S. 2006b. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 107: 2212–2222.CrossRefGoogle Scholar
  20. Lu, S.N., Wang, J.H., Chen, P.F., Tung, H.D., Tseng, P.L., Hung, C.H., Kee, K,M., Chen, C.H., Chang, K.C., Lee, C.M., Changchien, C.S., Chen, Y.D., Tsai, L.S., and Chen, T.H. 2008. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol. Biomarkers Prev. 17: 1813–1821.PubMedCrossRefGoogle Scholar
  21. Murawaki, Y., Ikuta, Y., Koda, M., Yamada, S., and Kawasaki, H. 1996. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J. Hepatol. 24: 148–154.PubMedCrossRefGoogle Scholar
  22. Rossi, E., Adams, L., Prins, A., Bulsara, M., de Boer, B., Garas, G., MacQuillan, G., Speers, D., and Jeffrey, G. 2003. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem. 49: 450–454.PubMedCrossRefGoogle Scholar
  23. Saitou, Y., Shiraki, K., Yamanaka, Y., Yamaguchi, Y., Kawakita, T., Yamamoto, N., Sugimoto, K., Murata, K., and Nakano, T. 2005. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J. Gastroenterol. 11: 476–481.PubMedGoogle Scholar
  24. Teare, J.P., Sherman, D., Greenfield, S.M., Simpson, J., Bray, G., Catterall, A.P., Murray-Lyon, I.M., Peters, T.J., Williams, R., and Thompson, R.P. 1993. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342: 895–898.PubMedCrossRefGoogle Scholar
  25. Toyoda, H., Kumada, T., Kiriyama, S., Sone, Y., Tanikawa, M., Hisanaga, Y., Yamaguchi, A., Isogai, M., Kaneoka, Y., and Washizu, J. 2006. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin. Gastroenterol. Hepatol. 4: 1170–1176.PubMedCrossRefGoogle Scholar
  26. Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., and Lok, A.S. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518–526.PubMedCrossRefGoogle Scholar
  27. Walsh, K.M., Fletcher, A., MacSween, R.N., and Morris, A.J. 2000. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J. Hepatol. 32: 325–330.PubMedCrossRefGoogle Scholar
  28. Wong, J.B., McQuillan, G.M., McHutchison, J.G., and Poynard, T. 2000. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90: 1562–1569.PubMedCrossRefGoogle Scholar
  29. Yuen, M.F., Cheng, C.C., Lauder, I.J., Lam, S.K., Ooi, C.G., and Lai, C.L. 2000. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31: 330–335.PubMedCrossRefGoogle Scholar
  30. Zhang, B.H., Yang, B.H., and Tang, Z.Y. 2004. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer. Res. Clin. Oncol. 130: 417–422.PubMedGoogle Scholar
  31. Zoli, M., Magalotti, D., Bianchi, G., Gueli, C., Marchesini, G., and Pisi, E. 1996. Efficacy of surveillance program for early detection of hepato-cellular carcinoma. Cancer 78: 977–985.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • Sheng-Nan Lu
    • 1
  • Jing-Houng Wang
    • 1
  • Kwong-Ming Kee
    • 1
  • Po-Lin Tseng
    • 1
  1. 1.Division of Hepatogastroenterology, Department of Internal MedicineKaohsiung Chang Gung Memorial HospitalNiaosungTaiwan

Personalised recommendations